## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -10.3% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($357.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis**
- Source: Newswire Canada | 20251216T130921 | Bullish | Relevance: 100%
- Alnylam Canada ULC has received Health Canada approval for AMVUTTRA® (vutrisiran), making it the first and only RNAi therapeutic authorized for treating cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). This approval expands AMVUTTRA's indication to include both cardiomyopathy manifestations and polyneuropathy, offering a significant advance for patients with this devastating and often misdiagnosed condition. Based on positive results from the HELIOS-B Phase 3 study, AMVUTTRA® demonstrated significant reductions in mortality and cardiovascular events, and improved functional capacity and quality of life for patients.

**2. Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251215T110934 | Bullish | Relevance: 100%
- Liontrust Investment Partners LLP reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 32.4% in the second quarter, selling over 6,000 shares. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating for ALNY with an average price target of $482.71. The article also notes recent insider selling activity, with corporate insiders divesting substantial shares in the last quarter.

**3. A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase**
- Source: Simply Wall Street | 20251214T091009 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) recently joined the Nasdaq 100 and repurchased some 2027 convertible notes, impacting its visibility and capital structure. Despite recent share price cooling, the company shows strong long-term momentum with significant year-to-date and 5-year returns. While currently trading at a discount to consensus targets and considered 19.3% undervalued based on TTR revenue scaling, its price-to-sales ratio is higher than industry averages, suggesting potential valuation risk.

**4. Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $351.00 by Analysts at Leerink Partners**
- Source: MarketBeat | 20251215T210733 | Somewhat-Bearish | Relevance: 100%
- Leerink Partners has reduced its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $370.00 to $351.00, maintaining a "market perform" rating despite the biopharmaceutical company's average "Moderate Buy" rating among analysts. Other firms have issued varying price target adjustments and ratings, while insider transactions reveal recent stock sales by company executives. Institutional investors have also significantly adjusted their holdings in ALNY.

**5. China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251214T101010 | Neutral | Relevance: 100%
- China Universal Asset Management Co. Ltd. significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 10.2% in the second quarter, selling over 3,000 shares. Despite this reduction, Alnylam remains a substantial holding for the firm, representing about 0.9% of its assets. The article also highlights recent insider selling from top executives and broadly positive analyst sentiment with a "Moderate Buy" rating and an average price target of $482.71.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Leerink Partner | $351 | $370 | -5% |
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Leerink Partner | main | Market Perform |
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Near-term weakness: 13.1% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 36.9x attractive for 114% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 43% YoY. Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $51.7B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 36.9 |
| Current P/E | 78.8 |
| YoY Growth | 113.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -11.8% to -10.3% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 14.3pp (needs >4.0% for momentum thesis). AM_20 at -10.3% indicates price below own 20MA trend. Underperforming sector by 10.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-6.43), momentum weakening. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -10.27% (CS: 2) | Weak |
| RSI_14 | 31.2 | Neutral |
| MACD Histogram | -6.43 | Bearish |
| vs SMA20 | 0.897x | Below |
| vs SMA50 | 0.869x | Below |
| vs SMA200 | 1.077x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $391.17
- **Stop Loss:** $357.57 (8.6% risk)
- **Target:** $424.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $11,343.93
- **Portfolio %:** 11.34%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*